Korea Yeul Hong Kim, R&D President of Yuhan, discusses the company’s transformation from a traditional Korean pharmaceutical business into an increasingly global innovator. He outlines Yuhan’s open innovation strategy, pipeline focus, investment in new modalities and AI-driven discovery, and its approach to global partnerships. Kim also discusses Korea’s pharmaceutical landscape, pricing…
Germany Money follows the science, and the science here in Bavaria is excellent Ralf Huss, Chief Executive of BioM, discusses how Bavaria has built one of Europe’s leading biotechnology ecosystems by connecting researchers, entrepreneurs, investors and global pharmaceutical companies. He highlights BioM‘s role in supporting more than 500 companies, accelerating start-ups…
Korea But Korea is genuinely active, with strong resources – scientifically sound, capable, and very motivated Kyong Hwa Park, Professor of Medical Oncology at Korea University College of Medicine, reflects on Korea’s transformation into a global oncology research hub, highlighting the impact of the K-MASTER precision medicine initiative, advances in cancer…
USA As precision medicine forces biopharma to rethink how it builds, runs, and scales laboratory and manufacturing infrastructure, the industry’s next competitive advantage will be found not in discovery, but in operational execution. Few are better positioned to make that argument than Michael Stubblefield, recently appointed CEO of PerkinElmer, who is…
Japan Patients in Japan deserve the same access to innovative treatments that patients in other markets have. Accelerating that access is what drives us Noriyuki Takai, CEO of EPS Corporation, outlines the CRO’s mission to help address Japan’s drug lag and drug loss by supporting faster access to innovative medicines. He…
Korea Korea has something that very few countries can claim: high-quality healthcare data at genuine population scale JK Lee, Vice President of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA), outlines Korea’s transition from a generics-driven industry to a global innovation hub. He highlights the government’s strategic support, a growing pipeline…
Korea If you concentrate on shared goals, collaboration and a unified voice follow naturally. Youngshin Lee, CEO of KRPIA, has built a career spanning more than three decades across pharmaceutical R&D, industry, and policy, advocating for collaboration between regulators, industry, and patients. Under her leadership, KRPIA has become a key voice…
Germany Scientific breakthroughs are redefining what is possible in cancer care, yet the true test lies in translating discovery into meaningful and lasting patient benefit. Michael Baumann reflects on how the DKFZ is helping shape Germany’s evolving oncology ecosystem through national research networks, precision medicine, clinical trial infrastructure, and a renewed…
Korea Seong-Wook Lee, CEO and founder of Rznomics, has spent more than two decades advancing trans-splicing ribozyme (TSR) technology as a novel RNA editing platform. After nearly 20 years in academia, he founded Rznomics to translate the approach into therapies for genetic and intractable diseases. With FDA-cleared clinical programmes, strategic partnerships,…
Korea Jurie Hwang is the Director of Public & International Affairs of KoreaBIO, the largest and most broadly constituted life sciences industry association in South Korea. With 650 member organisations spanning the entire value chain of the bio economy – from early-stage start-ups and venture capital firms to major conglomerates and…
Korea Dr Jeongseok Lee has served as President of the Korea Biomedicine Industry Association (KoBIA) since September 2020, backed by an outstanding 35-year career in public service and longstanding leadership in the healthcare sector. During a period marked by the unprecedented public health crisis of the COVID-19 pandemic and the significant…
APAC Ken Lee, Managing Director for Asia Pacific Clinical Business at Syneos Health, draws on a 20-year career across pharma, medicine, and CROs in Europe and Asia. He highlights Asia Pacific’s shift into a global clinical development hub, the rise of Greater China as a leading source of innovation, with mainland…
See our Cookie Privacy Policy Here
